Patient satisfaction with injection devices: A randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 4, 2012, Pages 448-455

  Paul, C ^a   Stalder, J F ^b   Thaci D ^c   Vincendon, P ^d   Brault, Y ^d   Kielar, D ^d   Tebbs, V ^d  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CLINIQUE DERMATOLOGIQUE   (France)

^c GOETHE UNIVERSITY   (Germany)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADULT; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; FEMALE; GENERAL MEDICAL INSTRUMENTATION; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRE FILLED PEN; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SAFETY; SYRINGE; TREATMENT DURATION;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 84858864908     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04093.x     Document Type: Article

References (25)

1. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010; 24: 1075-1082.
2. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
3. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethalendotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-1561. (Pubitemid 23219293)
4. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632. (Pubitemid 37523083)
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022. (Pubitemid 37448924)
6. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomised controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312. (Pubitemid 40933433)
7. Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006; 113: 156-162.
8. Rubin RR, Peyrot M,. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension versus alternative treatment strategies. Diabetes Care 2004; 27: 2495-2497. (Pubitemid 39281409)
9. Weidemann E, Unger J, Blair S, et al. An open label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptansuccinate formulations. ClinTher 2003; 25: 235-246. (Pubitemid 36206749)
10. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370. (Pubitemid 13098606)
11. Hibbard JH, Stockard J, Mahoney ER, Tusler M,. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 2004; 39: 1005-1026. (Pubitemid 38924690)
12. Feldman SR, Krueger GG,. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64: ii65-ii68. (Pubitemid 40288526)
13. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica1 1978; 157: 238-244. (Pubitemid 8387357)
14. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
15. Marteau TM, Bekker H,. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992; 31: 301-306.
16. Benzecri JP,. L'analyse des données. 2, L'analyse des correspondances: introduction, théorie, applications diverses notamment à l'analyse des questionnaires, programmes de calcul. Dunod, Paris, 1981.
17. Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther 2006; 28: 1619-1629. (Pubitemid 44838895)
18. Brown KK, Rehmus WE, Kimball AB,. Determining the relative importance of patient motivations for non-adherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607-613. (Pubitemid 44436629)
19. Picardi A, Mazzotti E, Gaetano P, et al. Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics 2005; 46: 556-564. (Pubitemid 41572177)
20. Zachariae R, Zachariae H, Blomqvist K, et al. Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol 2004; 18: 27-36. (Pubitemid 38159357)
21. Lora V, Gisondi P, Calza A, et al. Efficacy of a single educative intervention in patients with chronic plaque psoriasis. Dermatology 2009; 219: 316-321.
22. Sourial N, Wolfson C, Zhu B, et al. Correspondence analysis is a useful tool to uncover the relationships among categorical variables. J Clin Epidemiol 2010; 63: 638-646.
23. Briand S, Beresniak A, Nguyen T, et al. Assessment of yellow fever epidemic risk: an original multi-criteria modelling approach. PLoS Negl Trop dis. 2009; 3: e483.
24. Lefevre-Colau MM, Fayad F, Rannou F, et al. Frequency and interrelations of risk factors for chronic low back pain in a primary care setting. PLoS ONE 2009; 4: e4874.
25. Finzi A, Colombo D, Caputo A, et al. PSYCHAE study group. Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE study. J Eur Acad Dermatol Venereol 2007; 21: 1161-1169. (Pubitemid 47423402)